SCHEMBL3005306

SCHEMBL3005306

Cc1cc(C)cc(Cc2csc(N3CCN(S(=O)(=O)c4cccc(Cl)c4Cl)CC3)n2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.43
LMNA P02545 4/20 0.43
KMT2A Q03164 4/20 0.43
MAPT P10636 4/20 0.41
MEN1 O00255 3/20 0.41
ALDH1A1 P00352 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
KDM4E B2RXH2 2/20 0.39
POLB P06746 1/20 0.39
MAPK1 P28482 1/20 0.39
TP53 P04637 2/20 0.39
GAA P10253 1/20 0.38
PKM P14618 1/20 0.38
CHRM1 P11229 1/20 0.38
CNR1 P21554 1/20 0.37
CNR2 P34972 1/20 0.37
USP2 O75604 1/20 0.37
RECQL P46063 1/20 0.37
HSD17B10 Q99714 1/20 0.37
HTR6 P50406 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3015990 0.93 TSHR (0.42) TSHRLMNAKMT2AMAPTMEN1
SCHEMBL3011309 0.92 CHRM4 (0.43) LMNAKMT2AMAPTMEN1ALDH1A1
SCHEMBL2998544 0.91 TSHR (0.44) TSHRLMNAKMT2AMAPTMEN1
SCHEMBL3007745 0.90 TSHR (0.44) TSHRLMNAKMT2AMAPTMEN1
SCHEMBL3008933 0.90 LMNA (0.44) TSHRLMNAKMT2AMAPTMEN1
SCHEMBL3020120 0.89 MAPT (0.42) TSHRLMNAKMT2AMAPTMEN1
SCHEMBL3017663 0.89 KMT2A (0.47) TSHRLMNAKMT2AMAPTMEN1
SCHEMBL3018936 0.88 TSHR (0.46) TSHRLMNAKMT2AMAPTMEN1
SCHEMBL3010610 0.88 MAPT (0.45) TSHRLMNAKMT2AMAPTMEN1
SCHEMBL3014026 0.87 TSHR (0.44) TSHRLMNAKMT2AMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA TSHR 3320/4885LMNA 80/4885KMT2A 2680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.